Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1528 clinical trials
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and …

primary central nervous system lymphoma
lenalidomide
primary cns lymphoma
r-da-epoch
epoch-r
  • 0 views
  • 19 Feb, 2024
Safety and Early Signs of Efficacy of IL12-L19L19.

The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas and diffuse large B-cell lymphoma (DLBCL), after previous immune checkpoint blockade therapy. The primary objective of the study is to …

metastasis
gastric cancer
cancer, hepatocellular
bilateral salpingectomy
pet/ct
  • 0 views
  • 19 Feb, 2024
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

absolute neutrophil count
ibrutinib
neutrophil count
growth factor
igm level
  • 0 views
  • 19 Feb, 2024
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

rituximab
marginal zone lymphoma
prednisone
bortezomib
malt
  • 0 views
  • 19 Feb, 2024
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

chronic lymphocytic leukemia
cellular therapy
ejection fraction
oxygen saturation
induction chemotherapy
  • 0 views
  • 19 Feb, 2024
Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

The purpose of this study is to determine the predictive value of a mRNA signature and liquid biopsy in patients with Diffuse Large B cell lymphoma.

lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

rituximab
lenalidomide
lymphoma
non-hodgkin lymphoma
hodgkin's disease
  • 0 views
  • 19 Feb, 2024
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly …

monoclonal antibodies
immunoglobulins
monoclonal protein
multiple myeloma
cancer
  • 0 views
  • 19 Feb, 2024